Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | MMP7 | P09237 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23214314 | 1.00 | ACACB (0.47) | ACACBPHGDHMEN1KMT2AGPR139 | |
| SCHEMBL23214319 | 1.00 | ACACB (0.47) | ACACBPHGDHMEN1KMT2AGPR139 | |
| SCHEMBL11125918 | 0.81 | TRPA1 (0.42) | ACACBPHGDHMEN1KMT2AGPR139 | |
| SCHEMBL3124464 | 0.80 | PHGDH (0.51) | ACACBPHGDHMEN1KMT2AGPR139 | |
| SCHEMBL12505582 | 0.80 | PHGDH (0.51) | ACACBPHGDHMEN1KMT2AGPR139 | |
| SCHEMBL3105575 | 0.80 | PHGDH (0.51) | ACACBPHGDHMEN1KMT2AGPR139 | |
| SCHEMBL25236788 | 0.80 | ACACB (0.60) | ACACB | |
| SCHEMBL3708275 | 0.80 | ACACB (0.60) | ACACB | |
| SCHEMBL23214481 | 0.75 | CA1 (0.44) | ACACBKMT2A | |
| SCHEMBL23214480 | 0.75 | CA1 (0.44) | ACACBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| CN-114585603-A | Prostaglandin EP4Receptor antagonist compounds | 赫普泰雅治疗有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021069927-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | ACACB 3030/4885PHGDH 3018/4885MEN1 3802/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | ACACB 1380/4885PHGDH 3494/4885MEN1 669/4885 |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER1, PTGER4, PTGER2 | ACACB 3030/4885PHGDH 3018/4885MEN1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.